4.7 Article

Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biochemistry & Molecular Biology

Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis

Agnese Paderi et al.

Summary: This retrospective study suggests that early systemic steroids administration to manage irAEs may not have a detrimental effect on patient clinical outcome in NSCLC, melanoma, and RCC patients. Interestingly, patients who received steroids treatment after 30 days from the start of immunotherapy had significantly longer PFS.

MOLECULES (2021)

Article Oncology

Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas

Michelle Yeagley et al.

Summary: Research evaluated immune receptor recombinations in the TCGA sarcoma database using RNASeq, finding a correlation between T-cell receptor-alpha recombination reads and survival rate, T-cell biomarker expression, and tumor sample apoptosis signatures. Samples with specific complementarity showed better survival rates and higher granzyme expression.

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2021)

Review Immunology

A novel era of cancer/testis antigen in cancer immunotherapy

Xiaoyan Meng et al.

Summary: Immunotherapy is a treatment used for advanced cancers, focusing on tumor antigens like cancer/testis antigens (CTAs) and their use in cancer vaccines and T cell transfer therapy. CTAs are promising targets for vaccine or T cell therapy, enhancing the immune system's response.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Article Biochemistry & Molecular Biology

High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer

Boris I. Chobrutskiy et al.

Summary: Physicochemical assessments of adaptive immune receptor recombinations have led to correlations with subdivisions of diseases. In cancer settings, assessments of the immune receptor CDR3 domain have been used to establish chemical complementarity matches to mutant amino acids, correlating with survival and gene expression distinctions. This approach has been expanded to include a more comprehensive representation of T-cell receptor CDR3 interactions with mutant amino acids, showing significant patient subdivisions and enabling more efficient development of patient immunology-related prognostic tools and therapies.

MOLECULAR IMMUNOLOGY (2021)

Article Multidisciplinary Sciences

The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation

Timothy D. Martin et al.

Summary: This study suggests that clonal selection of recurrent mutations in cancer is mainly driven by the tumor's requirement to avoid the adaptive immune system, highlighting the important role of adaptive immunity in the development and progression of tumors.

SCIENCE (2021)

Article Oncology

Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates

Monica Hsiang et al.

Summary: Uterine cancer has been associated with a T-cell immune response that leads to increased survival. Bioinformatics approaches were used to explore interactions between T-cell receptor and tumor mutant peptide sequences in endometrioid uterine cancer patients. The study found that complementary groups with TTN mutants had increased disease-free survival, independent of HLA class II binding.

TRANSLATIONAL ONCOLOGY (2021)

Article Oncology

T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer

Boris I. Chobrutskiy et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Article Genetics & Heredity

Landscape of tumor-infiltrating T cell repertoire of human cancers

Bo Li et al.

NATURE GENETICS (2016)

Review Immunology

The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation

Kankana Bardhan et al.

FRONTIERS IN IMMUNOLOGY (2016)

Article Microbiology

V(D) J Recombination: Mechanism, Errors, and Fidelity

David B. Roth

MICROBIOLOGY SPECTRUM (2014)

Review Oncology

Immunosuppression and risk of cervical cancer

Pierre-Antoine Dugue et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2013)

Article Biochemistry & Molecular Biology

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Jianjiong Gao et al.

SCIENCE SIGNALING (2013)

Article Gastroenterology & Hepatology

Intestinal Inflammation and Cancer

Thomas A. Ullman et al.

GASTROENTEROLOGY (2011)

Review Oncology

Cancer incidence and risk factors after solid organ transplantation

Claire M. Vajdic et al.

INTERNATIONAL JOURNAL OF CANCER (2009)

Article Biochemistry & Molecular Biology

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

Luiz Gonzaga Almeida et al.

NUCLEIC ACIDS RESEARCH (2009)

Article Gastroenterology & Hepatology

Inflammation and cancer - IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation

SH Itzkowitz et al.

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2004)